NasdaqGS - Nasdaq Real Time Price ? USD Vertex Pharmaceuticals Incorporated (VRTX) Follow Compare 484.30 -0.52 (-0.11%) At close: October 15 at 4:00 PM EDT 484.30 0.00 (0.00%) Pre-Market: 8:05 AM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Vertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to Note Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $484.94, moving +0.67% from the previous trading session. Zacks ? yesterday VRTX -0.11% Got $1,000? 2 Magnificent Growth Stocks to Buy and Hold Forever These profitable companies are facing long-term growth runways. Motley Fool ? 2 days ago VRTX -0.11% PLTR 3 No-Brainer Growth Stocks to Buy in October These stocks look like slam-dunk picks for growth investors. Motley Fool ? 3 days ago VRTX -0.11% LLY -1.74% NVO Vertex to Announce Third Quarter 2024 Financial Results on November 4th BOSTON, October 10, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Third Quarter 2024 Earnings Call." Business Wire ? 5 days ago VRTX -0.11% October 2024's US Stocks That May Be Trading Below Estimated Fair Value As the U.S. stock market continues its impressive rally, with the S&P 500 and Dow Jones Industrial Average reaching record highs, investors are increasingly focused on identifying opportunities that may be trading below their estimated fair value. In this buoyant market environment, a good stock is often characterized by strong fundamentals and potential for growth that hasn't yet been fully recognized by the broader market. Simply Wall St. ? 6 days ago VRTX -0.11% PLTR AMD Vertex Pharmaceuticals Inc (VRTX) Q2 2024 Earnings Call Highlights: Navigating Growth Amidst ... Vertex Pharmaceuticals Inc (VRTX) reports robust revenue growth and raises guidance, while addressing acquisition-related losses and strategic hurdles. GuruFocus.com ? 6 days ago VRTX -0.11% 2 Biotech Stocks to Buy Hand Over Fist in October These longtime leading biotech stocks still have plenty of upside ahead. Motley Fool ? 6 days ago VRTX -0.11% AMGN +0.14% Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store. Zacks ? 6 days ago VRTX -0.11% Is Vertex Pharmaceuticals Incorporated (VRTX) Positioned for Continued Success in Cystic Fibrosis and Beyond? We recently published a list of Renaissance Technologies Portfolio: 10 Best Stocks To Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other best stocks to buy which are part of the Renaissance Technologies portfolio. Renaissance Technologies is an American hedge fund that specializes […] Insider Monkey ? 7 days ago VRTX -0.11% Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $448.16, signifying a -1.57% move from its prior day's close. Zacks ? 8 days ago VRTX -0.11% ^GSPC Zacks Market Edge Highlights: Vertex, Zillow RH, Super Micro Computer, Yum China Vertex, Zillow RH, Super Micro Computer, Yum China have been highlighted in this Market Edge article. Zacks ? 9 days ago YUMC VRTX -0.11% ZG Insider Trades: How to Find the Top Stocks Tracey is joined by Asif Suria, author of The Event-Driven Edge in Investing, to talk about how to get an edge from insider trading. Zacks ? 11 days ago VRTX -0.11% YUMC ZG DRI Healthcare Trust Buying Payment Streams Based On Gene-Editing Technology For US$57 Million DRI Healthcare Trust Buying Payment Streams Based On Gene-Editing Technology For US$57 Million PREMIUM MT Newswires ? 12 days ago VRTX -0.11% HR EDIT 3 Top Stocks That Could Still Rocket Higher in 2024 Upcoming Food and Drug Administration decisions could push these stocks through the roof. Motley Fool ? 12 days ago BBIO VRTX -0.11% PTCT 2 Superior Growth Stocks That Are Screaming Buys Right Now These companies have plenty of growth runway left. Motley Fool ? 12 days ago VRTX -0.11% NFLX Reasons that Lifted Vertex Pharmaceuticals Incorporated (VRTX) in Q2 PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund modestly underperformed the S&P 1500 Health Care Index in the quarter which declined 1.1%. Security selection within pharmaceuticals, MedTech, and health care provides & services contributed the most value during the quarter, […] Insider Monkey ? 12 days ago VRTX -0.11% 5 FDA decisions to watch in the fourth quarter Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business. BioPharma Dive ? 15 days ago BBIO VRTX -0.11% CELG-RT Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $465.08, denoting a +0.48% change from the preceding trading day. Zacks ? 15 days ago VRTX -0.11% Vertex Pharmaceuticals presents vanzacaftor/tezacaftor/deutivacaftor data Vertex Pharmaceuticals announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor – the potential next-in-class triple combination medicine – will take place at the North American Cystic Fibrosis Conference, or NACFC. Vertex also announced presentations describing long-term outcomes in people with cystic fibrosis ages 2 to 11 years taking Trikafta, demonstrating consistent and sustained improvements across multipl TipRanks ? 19 days ago VRTX -0.11% Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest? The average brokerage recommendation (ABR) for Vertex (VRTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock? Zacks ? 19 days ago VRTX -0.11% Performance Overview Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return VRTX S&P 500 YTD +19.02% +21.92% 1-Year +30.54% +34.37% 3-Year +166.25% +31.03%
